Here, we studied the underlying mechanism of aldosterone (Aldo)-induced vascular endothelial cell damages by focusing on ceramide. We confirmed that Aldo (at nmol/L) inhibited human umbilical vein endothelial cells (HUVEC) survival, and induced considerable cell apoptosis. We propose that ceramide (mainly C18) production might be responsible for Aldo-mediated damages in HUVECs. Sphingosine-1-phosphate (S1P), an anti-ceramide lipid, attenuated Aldo-induced ceramide production and following HUVEC damages. On the other hand, the glucosylceramide synthase (GCS) inhibitor PDMP or the ceramide (C6) potentiated Aldo-induced HUVEC apoptosis. Eplerenone, a mineralocorticoid receptor (MR) antagonist, almost completely blocked Aldo-induced C18 ceramide production and HUVEC damages. Molecularly, ceramide synthase 1 (CerS-1) is required for C18 ceramide production by Aldo. Knockdown of CerS-1 by targeted-shRNA inhibited Aldo-induced C18 ceramide production, and protected HUVECs from Aldo. Reversely, CerS-1 overexpression facilitated Aldo-induced C18 ceramide production, and potentiated HUVEC damages. Together, these results suggest that C18 ceramide production mediates Aldo-mediated HUVEC damages. MR and CerS-1 could be the two signaling molecule regulating C18 ceramide production by Aldo.
Citation: Zhang Y, Pan Y, Bian Z, Chen P, Zhu S, Gu H, et al. (2016) Ceramide Production Mediates Aldosterone-Induced Human Umbilical Vein Endothelial Cell (HUVEC) Damages. PLoS ONE 11(1): e0146944. https://doi.org/10.1371/journal.pone.0146944
Editor: Christina Lynn Addison, Ottawa Hospital Research Institute, CANADA
Received: October 20, 2015; Accepted: December 23, 2015; Published: January 20, 2016
Copyright: © 2016 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: This study was funded by Science Fund Project of Shanghai Jiaotong University School of Medicine (no. 13XJ10056, to CH) and Science Research Tasks of Shanghai Municipal Commission of Health and Family Planning (201440331, to CH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Recent studies have implied an important role of aldosterone (Aldo) in the pathogenesis of multiple vascular diseases [1,2]. Studies have demonstrated that plasma Aldo level is significantly elevated in the vascular disease patients [1,2]. Exogenous infusion of Aldo could induce direct deleterious effect on vascular tissues in animal models [3,4,5,6,7,8]. Vascular endothelial cell apoptosis is recognized as the fundamental step in the progression of vascular sclerosis . Yet, the underlying molecular mechanisms are not fully studied. To this regard, Aldo was added to cultured vascular epithelial cells, and associated signaling changes were analyzed [10,11]. In the current study, we studied the possible role of ceramide in the process.
Existing evidences have established ceramide as an important player in apoptosis induction [12,13,14]. A number of cytotoxic agents were shown to induce ceramide production, mediating following cell death [12,13,14]. Increased ceramide production in multiple human cell lines could lead to growth inhibition, cell apoptosis, differentiation and senescence [15,16]. Anti-cancer chemotherapeutic agents, including taxol, doxorubicin as well as several natural compounds were shown to induce cellular ceramide production, mediating subsequent cell apoptosis [15,16].
In this study, we hypothesized that Aldo-induced vascular endothelial cell apoptosis may be accompanied with increased ceramide production, which might contribute significantly to vascular cell damages. To test this hypothesis, we examined the cellular ceramide level in Aldo-treated human umbilical vein endothelial cells (HUVECs). Pharmacological and genetic strategies were applied to alter cellular ceramide level, Aldo-induced HUVEC cytotoxicity in these conditions was tested.
Material and Methods
2.1. Chemicals, reagents and antibodies
Aldosterone (Aldo), L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) sphingosine-1-phosphate (S1P) and Eplerenone were obtained from Sigma-Aldrich Chemicals (Sigma, St. Louis, MO). The cell-permeable short chain Ceramide (C6) was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). The pan-caspase inhibitor z-VAD-fmk, the caspase-3 specific inhibitors z-DVED-fmk and AC-DEVD-CHO were purchased from Calbiochem (Shanghai, China). All the antibodies utilized in this study were obtained from Abcam (Danvers, MA).
2.2. HUVEC culture
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cord veins by collagenase I (0.25%, Sigma) digestion. The harvested cells were grown in medium 199 (Gibco, Shanghai, China) containing 15% heat-inactivated fetal calf serum (FCS, Gibco), endothelial cell growth supplement (ECGS, 30 μg/mL, Sigma), epidermal growth factor (EGF 10 ng/mL, Sigma), 100 U/mL penicillin, and 100 μg/mL streptomycin. After 3–5 passages, HUVECs were collected for experimental use. All research involving human samples have been approved by the Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine Institutional Review Board (IRB) members: Wang Li, Jing Li, Gang Wu and Xiao-jing Li. The approval number is NO2013025. All clinical investigation has been conducted according to the principles expressed in the Declaration of Helsinki. Informed written consents have been obtained from each participants.
2.3. MTT cell survival assay
HUVEC viability was measured by the 3-[4,5-dimethylthylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT, Sigma) assay. Briefly, HUVECs were seeded onto 96-well plate at a density of 3 x 10 3 cells/well. After applied treatments, twenty μL/well of MTT tetrazolium solution (5 mg/mL) was added, and incubated in a CO2 incubator for additional 3 hours. Finally, the medium was aspirated, and 150 mL/well of DMSO (Sigma) was added to dissolve formazan crystals. The absorbance of each well was obtained using a plate reader at the wavelength of 490 nm. OD value was utilized as an indicator of cell viability.
2.4. Lactate dehydrogenase (LDH) assay
LDH content released to the conditional medium indicates the level of cell death. After applied treatment, HUVEC medium LDH was assayed by a LDH detection kit from Roche Applied Science (Shanghai, China). LDH release % = LDH released in conditional medium/(LDH released in conditional medium + LDH in cell lysates) x 100%. HUVECs were lysed by 1% Triton X-100.
2.5. Fragmented DNA detection by ELISA
Nucleosomal DNA fragmentation is one biological marker of cell apoptosis . Fragmented DNA was assessed by measuring DNA-associated with nucleosomal histones through a specific two-site ELISA with an anti-histone primary antibody, and a secondary anti-DNA antibody, according to the manufacturer's instructions (Roche Applied Science, Shanghai, China). ELISA OD at 450 nm was recorded as a quantitative measurement of HUVEC apoptosis.
2.6. Annexin V FACS assay of cell apoptosis
Apoptosis was detected by an Annexin-V-FITC apoptosis detection kit (BD Pharmingen, San Diego, CA). Briefly, following applied treatment, HUVECs were harvested and washed twice with cold PBS, and then incubated for 15 min with Annexin-V-FITC and propidium iodide (PI). Both early (Annexin V+/PI−) and late (Annexin V+/PI+) apoptotic cells were gated by the fluorescence activated cell sorter (FACS) machine (BD Pharmingen). The percentage of Annexin V stained HUVECs was utilized as another quantitative measurement of cell apoptosis.
2.7. Caspase-3 activity assay
After applied treatment, cytosolic proteins of approximately 1 × 106 HUVECs were extracted. Thirty μg of cytosolic extracts per sample were added to caspase assay buffer (312.5 mm HEPES, pH 7.5, 31.25% sucrose, 0.3125% CHAPS) with benzyloxycarbonyl-DEVD-7-amido-4-(trifluoromethyl)coumarin as the substrate (Calbiochem). After 2 hours of incubation at 37°C, the release of 7-amido-4-(trifluoromethyl)coumarin (AFC) was quantified, using a Fluoroskan system (Thermo-Labsystems, Helsinki, Finland) set to an excitation value of 355 nm and emission value of 525 nm as described .
2.8. Western blot
After treatment, the cells were harvested with trypsinization, centrifuged and lysed in lysis buffer (Biyuntian, Wuxi, China). Total protein was quantified by the Bio-Rad assay kit, mixed with 5 times sample buffer and boiled at 95°C for 5 min. Equal amount of proteins (30 μg/sample) were separated by electrophoresis in SDS-PAGE, transferred to the PVDF membrane, and were detected with the specific antibody. The immuno-reactive proteins after incubation with appropriately labeled secondary antibody were detected with an enhanced chemiluminescence (ECL) detection kit (Amersham, Buckinghamshire, UK). Band intensity was quantified by ImageJ software (NIH) after normalization to the corresponding loading control.
2.9. Enzymatic measurement of total cellular ceramide
The total cellular ceramide level was analyzed with the help from Dr. Ming Xu’ lab at Tongji University (Shanghai, China) utilized the 1,2-diacylglycerol (DAG) kinase method as described [19,20], and was valued as fmol by nmol of phospholipid. Its level in the treatment group was expressed as the fold change of the untreated control group. Each measurement was performed triplicate.
2.10. Liquid chromatography-mass spectrum (LC-MS) detection of individual cellular ceramide
Individual ceramide production was detected by LC-MS method as previously described [21,22]. Briefly, after treatment, cells were resuspended in PBS, and the lipids were extracted with ethyl acetate/isopropanol/water (60/30/10, v/v) [21,22]. Extracted lipids were then dried under N2, which was solubilized in 56.7% methanol, 33.3% ethanol, 10% water, and derivatized with ortho-phthaldialdehyde (Sigma) . Thereafter, the lipids were separated on a C18 column [21,22] and analyzed by a serial arrangement of Hypersil C8/150×3.2 mm column followed by a mass spectrum (MS) detector (Thermo Finnigan TSQ 7000 triple quadrupole mass spectrometer) operating in a multiple reaction monitoring positive ionization mode. Non-natural individual ceramides (C18/C20/C22/C24) (Avanti) were utilized as the internal standards. Results were normalized to total phospholipid contents and expressed as pmol ceramide/nmol phosphate.
2.11. Ceramide synthase 1 (CerS-1) shRNA knockdown
To knockdown ceramide synthase 1 (CerS-1), CerS-1-shRNA (h) lentiviral particles (sc-62543-V, Santa Cruz Biotech, Santa Cruz, Ca) (10 μL/mL medium) were added directly to HUVECs, the infection took 48 hours. Afterwards, the CerS-1 expression was verified by Western blot. Control cells were infected with same amount of scramble shRNA lentiviral particles (sc-108080-V, Santa Cruz) (10 μL/mL medium, 48 hours).
2.12. Ceramide synthase 1 (CerS-1) over-expression
The full-length human CerS-1 cDNA was synthesized by Genechem (Shanghai, China). The cDNA was inserted into pSuper-puro plasmid (Youbio, Beijing, China). The CerS-1 plasmid or the empty vector (pSuper-puro) was then transfected into HEK-293 cells with plasmids encoding viral packaging proteins VSVG and Hit-60 (Promega)  using Lipofectamine 2000 (Invitrogen). The virus-containing supernatants were collected and filtered, and were then added to HUVECs for 48 hours. CerS-1 over-expression in infected cells was confirmed by Western blots.
3.1. Aldosterone exerts cytotoxic effects to cultured HUVECs
We first examined the potential effect of Aldo on cultured vascular cells. Primary HUVECs were treated with indicated concentrations of Aldo, cells were future cultured. MTT cell viability results in Fig 1A demonstrated that Aldo dose-dependently inhibited HUVEC survival. HUVEC viability OD was 75.8 ±4.6%, 55.5 ± 3.5% and 29.0 ± 2.9% of untreated control after 10, 100 and 1000 nM of Aldo treatment, respectively (Fig 1A). Further, Aldo at 100 nM showed a time-dependent manner in inhibiting HUVEC survival (Fig 1B). A significant viability reduction was observed 24 and 48 hours after Aldo treatment (Fig 1B). At the meantime, the level of medium LDH of Aldo-treated HUVECs was significantly increased, suggesting cell death (Fig 1C and 1D). These results together demonstrate that Aldo is cytotoxic when added directly to cultured HUVECs.
HUVECs were either left untreated (“Ctrl”), or treated with applied concentrations of aldosterone (1–1000 nM) for indicated time point, cell survival was tested by MTT assay (A and B), and cell death was tested by LDH release assay (C and D). Data were expressed as the mean ± SD. For each assay, n = 5. Experiments in this figure were repeated four times, and similar results were obtained. * p < 0.05 vs. “Ctrl” group.
3.2. Aldosterone induces caspase-3-dependent apoptotic death in HUVECs
Next, we studied the potential effect of Aldo on HUVEC apoptosis. Three independent apoptosis assays were performed. Results demonstrated clearly that Aldo dose-dependently induced apoptosis in HUVECs (Fig 2A–2C). The percentage of Annexin V positive cells was significantly increased following Aldo (10–1000 nM, 24 hours) treatment (Fig 2A). Fig 2A lower panel demonstrated representative Annexin V FACS images of HUVECs before (“Ctrl”) and after Aldo (10/100 nM, 24 hours) treatment. The apoptosis histone-DNA ELISA OD (Fig 2B) and the caspase-3 activity (Fig 2C, lower panel) were also increased with Aldo (100–1000 nM) treatment in HUVECs. In addition, the level of cleaved-caspase-3 was significantly increased following Aldo treatment in HUVECs, while regular caspase-3 level was decreased (Fig 2C, upper panel). These results indicate that Aldo induced significant apoptosis activation in HUVECs.
HUVECs were treated with applied concentrations of aldosterone (1–1000 nM) for indicate time, cell apoptosis was evidenced by Annexin V FACS assay (A, representative FACS images were shown in lower panel), histone DNA ELISA assay (B), caspase-3 activity assay (C, lower panel) and Western blot assaying of cleavead-caspase-3 (“C-Caspase-3”) (C, upper panel). HUVECs, pre-treated with the caspase-3 inhibitor z-DVED-fmk (“ZDVED”, 25 μM)/AC-DEVD-CHO (“AC-DEVD”, 25 μM), or the pan caspase inhibitor z-VAD-fmk (“ZVAD”, 25 μM) for 1 hour, were stimulated with aldosterone (100 nM), caspase-3 activity and cell apoptosis were analyzed by the caspase-3 activity assay (D) and Annexin V FACS assay (E), respectively; Cell survival was tested by the MTT assay (F). Data were expressed as the mean ± SD. For each assay, n = 5. Experiments in this figure were repeated three times, and similar results were obtained. * p < 0.05 vs. “Ctrl” group. # p < 0.05 vs. aldosterone (100 nM) only group (D-F).
To investigate the potential role of apoptosis activation in Aldo-induced HUVEC cytotoxicity, various caspase inhibitors were utilized: including the specific caspase-3 inhibitors (z-DVED-fmk and AC-DEVD-CHO), and the pan caspase inhibitor (z-VAD-fmk). Results showed that these inhibitors almost completely blocked Aldo-induced caspase-3 activation and following HUVEC apoptosis (Fig 2D and 2E). As a result, Aldo-induced HUVEC cytotoxicity, evidenced by viability OD reduction, was remarkably attenuated with the co-treatment of the caspase inhibitors (Fig 2F). These caspase inhibitors alone had no effect on HUVEC survival or apoptosis (Data not shown). Thus, Aldo induces caspase-3-dependent apoptosis in cultured HUVECs.
3.3. Aldosterone mainly induces C18 ceramide production in HUVECs
We next aimed to understand the potential role of ceramide in Aldo-induced vascular cell damages. At first, diacylglycerol (DAG) kinase assay  was performed to determine total cellular ceramide. Results in Fig 3A demonstrated that Aldo induced ceramide production in HUVECs (Fig 3A), the level of total cellular ceramide was significantly increased following Aldo (10–1000 nM) treatment (Fig 3A). To study the role of ceramide in Aldo-induced apoptosis, pharmacological strategy was applied. As shown in Fig 3B, Aldo (100 nM)-induced ceramide production in HUVECs was inhibited by sphingosine-1-phosphate (S1P, a sphingosine counteracting ceramide’s effect ), but was potentiated by PDMP, which is a glucosylceramide synthase (GCS) inhibitor  (Fig 3B). Remarkably, Aldo (100 nM)-induced cytotoxicity (Fig 3C) and apoptosis (tested by caspase-3 activity and apoptosis ELISA assay, Fig 3D and 3E) were significantly inhibited by S1P, but were exacerbated by PDMP (Fig 3C–3E). Further, the actions by Aldo in HUVECs were mimicked by the exogenously-added cell-permeable ceramide (C6) (Fig 3C–3E). In addition, ceramide (C6) also enhanced Aldo-mediated HUVEC cytotoxicity (Fig 3C–3E). Together, these results indicate that ceramide production is important for Aldo-mediated HUVEC damages.
HUVECs were treated with applied concentrations of aldosterone (1–1000 nM) for 4 hours, total cellular ceramide level was analyzed by the DAG kinase assay, and was normalized to the untreated control (“Ctrl”) group (A), individual ceramide level was detected by LS-MS assay as described (F). HUVECs, pretreated with PDMP (10 μM), S1P (10 μM) or C6 ceramide (25 μM) for 1 hour, were stimulated with aldosterone (100 nM), cellular ceramide was analyzed (B); Cell survival was tested by MTT assay (C), and cell apoptosis was tested by the caspase-3 activity assay (D) or the Histone DNA ELISA assay (E). For each assay, n = 3. Experiments in this figure were repeated three times, and similar results were obtained. * p < 0.05 vs. “Ctrl” group. ** p < 0.05 (C-E).
Next, we wanted to know which individual ceramide was induced by Aldo in HUVECs. The liquid chromatography-mass spectrum (LC-MS) method was applied (See method). As shown in Fig 3F, C18 was the major individual ceramide in HUVECs. It level was significantly increased following Aldo treatment (10–1000 nM) (Fig 3F). Level of other individual ceramide, including C20, C22 and C24, was dramatically lower than that of C18 (Fig 3F). Among these individual ceramide, only C24 ceramide level was slightly increased following Aldo (100/1000 nM) treatment in HUVECs (Fig 3F). Other individual ceramide (C12, C14 etc) level was even lower (Data not shown). There results indicate that Aldo mainly induces C81 ceramide production in HUVECs.
3.4. Eplerenone blocks aldosterone-induced ceramide production and following HUVEC cytotoxicity
Next, we studied the molecular mechanisms underlying ceramide production by Aldo. Eplerenone, an Aldo mineralocorticoid receptor (MR) antagonist , was applied. Results demonstrated that Eplerenone almost completely blocked Aldo-induced C18, C24 and total ceramide production in HUVECs (Fig 4A–4C), indicating a critical role of MR in mediating ceramide production by Aldo. As a result, Aldo-induced HUVEC death (Fig 4D, viability reduction) and apoptosis (Fig 4E and 4F, tested by caspase-3 activity assay and histone-DNA ELISA assay) were significantly inhibited by the MR antagonist. These results indicate that functional MR is required for Aldo-induced ceramide production and HUVEC damages.
HUVECs, pretreated with Eplerenone (10 μM) for 1 hour, were stimulated with aldosterone (100 nM), C18 ceramide (A, LS-MS assay), C24 ceramide (B, LS-MS assay), and total ceramide (C, DAG kinase assay) were analyzed after 4 hours; Cell viability was tested by MTT assay (D), and cell apoptosis was tested by the caspase-3 activity assay (E) and Histone DNA ELISA assay (F). For each assay, n = 3. Experiments in this figure were repeated three times, and similar results were obtained. * p < 0.05.
3.5. Ceramide synthase 1 mediates aldosterone-induced C18 ceramide production and following HUVEC damages
The above results demonstrated that Aldo mainly induced C18 ceramide production in HUVECs. Ceramide synthase 1 (CerS-1) is a key enzyme responsible for C18 ceramide synthesis . We thus tested whether CerS-1 was also involved in Aldo-mediated C18 ceramide production. The shRNA method was applied. Western blot results in Fig 5A showed that expression of CerS-1 was remarkably downregulated by targeted CerS-1 shRNA. Two CerS-1 shRNA-expressing HUVEC clones (-1/-2) were selected (Fig 5A). Notably, Aldo (100 nM)-induced C18 ceramide production was remarkably inhibited by CerS-1 shRNA (Fig 5B). On the other hand, Aldo-mediated C24 ceramide production was not affected by CerS-1 knockdown (Fig 5C). Importantly, Aldo-exerted HUVEC viability reduction (Fig 5D) and apoptosis (Fig 5E and 5F) were significantly attenuated with CerS-1 knockdown. These results indicate that CerS-1 and it-mediated C18 ceramide production is critical in regulating Aldo’s actions in HUVECs.
Expression of CerS-1 and tubulin (the equal loading) in HUVECs expressing scramble control shRNA or CerS-1 shRNA (two colonies) was shown (A), CerS-1 expression (vs. tubulin) was quantified (A). Above cells were treated with or without aldosterone (100 nM), C18 and C24 ceramide production (B and C), cell survival (D) and cell apoptosis (Caspase-3 activity, E and Histone DNA EILSA OD, F) were tested. Expression of CerS-1 and β-actin (the equal loading) in HUVECs expressing CerS-1-cDNA or the empty vector (p-Super-puro) was shown, CerS-1 expression (vs. β-actin) was quantified (G); Aldo (100 nM)-induced C18 ceramide production (H, 4 hours), cell viability reduction (I, 24 hours), and caspase-3 activity (J, 12 hours) in above cells were tested. For each assay, n = 3. Experiments in this figure were repeated three times, and similar results were obtained. * p < 0.05.
To further confirm the role of CerS-1 in Aldo-mediated cytotoxicity, over-expression strategy was utilized. We successfully constructed a CerS-1-cDNA plasmid (see method). Results in Fig 5G demonstrated CerS-1 over-expression in the HUVECs with the plasmid. CerS-1 over-expression facilitated Aldo-induced C18 ceramide production (Fig 5H). As a result, Aldo-exerted HUVEC death (viability reduction, Fig 5I) and apoptosis (caspase-3 activation, Fig 5J) were potentiated with CerS-1 over-expression (Fig 5G). Together, these results again suggest that CerS-1 is important for Aldo-induced C18 ceramide production and HUVEC cytotoxicity.
Ceramide is a well-known apoptosis mediator in response to various cytotoxic stimuli [28,29]. In the current study, we showed that ceramide production is also required for Aldo-mediated deleterious effects in cultured HUVECs. S1P attenuated Aldo-induced ceramide production, thus inhibiting following HUVEC damages. Eplerenone, a mineralocorticoid receptor (MR) antagonist, almost completely blocked Aldo-induced (C18/C24) ceramide production and subsequent HUVEC death/apoptosis. Importantly, exogenously-added cell-permeable ceramide (C6) was shown to mimic Aldo’s actions, and induced significant HUVEC damages. Molecularly, CerS-1 could be the enzyme for C18 ceramide production by Aldo. CerS-1 knockdown attenuated Aldo-induced C18 ceramide production, and protected HUVECs from Aldo. CerS-1 over-expression, on the other hand, sensitized Aldo-induced C18 ceramide production and HUVEC apoptosis. Together, these results suggest that ceramide (mainly C18) production is critical for Aldo-mediated HUVEC damages.
Aldo is a key regulator of blood pressure and electrolytic balance. Recent evidences, however, have demonstrated that increased Aldo could exert a number of deleterious effects to the cardiovascular system, including myocardial necrosis and fibrosis, vascular stiffening, reduced fibrinolysis as well as endothelial dysfunction and injuries, catecholamine release, and cardiac arrhythmias [2,3,30,31,32,33]. Thus, excessive Aldo contributes to the development and progression of a number of cardiovascular diseases, including hypertension, congestive heart failure, chronic kidney disease, coronary artery disease, and stroke [2,3,30,34]. Aldo has displayed a number of direct actions to epithelial cells [32,35,36]. In the current study, we showed that Aldo activated MR-CerS-1 pathway to induce (C18) ceramide production, mediating HUVEC damages.
Studies have shown that Aldo activated two pathways to exert its action. One is the classic MR pathway, and the other is the novel MR-independent pathway . Here, we showed that Aldo-induced (C18) ceramide production and HUVEC damages were almost completely blocked by the MR antagonist Eplerenone, suggesting the pivotal role of classic MR pathway in the process. Yet, besides ceramide production, activation of MR by Aldo in epithelial cells could exert a number of other actions, including activation of several downstream signalings (i.e. endoplasmic reticulum stress and ERK-MAPK)  and production of reactive oxygen species (ROS) . Further studies will be needed to explore the detailed signaling mechanisms of CerS-1 activation/ceramide production by Aldo-MR. In particularly, if there is a link between CerS-1 activation and other known actions of Aldo. More importantly, it will also be critical to know if ceramide production could affect other endpoints of Aldo in epithelial cells, including epithelial-to-mesenchymal transition (EMT) , production of vascular endothelial growth factor (VEGF)  and adhesion molecule [30,38], as well as vascular nitric oxide (NO) bioavailability inhibition [39,40].
Cells are capable of removing excess ceramide through various metabolic clearance pathways [41,42]. As a matter of fact, agents that inhibit metabolically clearance of ceramide could lead to a pro-apoptotic outcome [43,44,45,46]. In the current study, we showed that co-administration of PDMP, the glucosylceramide synthase (GCS) inhibitor [46,47], facilitated Aldo-induced ceramide accumulation, therefore enhancing HUVEC apoptosis and cytotoxicity. Other studies using similar strategies showed that PDMP sensitized cytotoxicity by several chemo-agents (Taxol ,Vincristine  and curcumin ) in different cancer cells. These results further confirm the involvement of ceramide in Aldo-induced actions in HUVECs.
In conclusion, our results suggest that ceramide (mainly C18) production mediates Aldo-induced damages to cultured HUVECs. Functional MR and CerS-1 could be the signaling molecule regulating C18 ceramide production by Aldo. Amelioration of Aldo-induced (C18) ceramide production could be a novel strategy for the treatment of Aldo-associated vascular disease.
Conceived and designed the experiments: YZ YP HG LG CH. Performed the experiments: YZ YP ZB PC SZ HG LG. Analyzed the data: YZ YP CH. Contributed reagents/materials/analysis tools: YZ YP ZB PC SZ HG LG CH. Wrote the paper: YZ CH.
- 1. Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y (2006) Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol 47: 609–613. pmid:16680076
- 2. Epstein M (2001) Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 37: 677–688. pmid:11273866
- 3. Calhoun DA (2006) Aldosterone and cardiovascular disease: smoke and fire. Circulation 114: 2572–2574. pmid:17159070
- 4. Hillaert MA, Lentjes EG, Beygui F, Kemperman H, Asselbergs FW, Nathoe HM, et al. (2011) Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data. Am Heart J 162: 585–596. pmid:21982648
- 5. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, et al. (2004) Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109: 2213–2220. pmid:15123520
- 6. Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG, et al. (2008) Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 29: 2489–2496. pmid:18757359
- 7. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W (2010) Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 31: 1237–1247. pmid:20200015
- 8. Vantrimpont P, Rouleau JL, Ciampi A, Harel F, de Champlain J, Bichet D, et al. (1998) Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 19: 1552–1563. pmid:9820995
- 9. Farquharson CA, Struthers AD (2002) Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 103: 425–431.
- 10. Lu JP, Li X, Jin YL, Chen MX (2014) Endoplasmic reticulum stress-mediated aldosterone-induced apoptosis in vascular endothelial cells. J Huazhong Univ Sci Technolog Med Sci 34: 821–824. pmid:25480576
- 11. Qiao W, Zhang W, Shao S, Gai Y, Zhang M (2015) Effect and mechanism of poly (ADP-ribose) polymerase-1 in aldosterone-induced apoptosis. Mol Med Rep 12: 1631–1638. pmid:25872931
- 12. Lin CF, Chen CL, Lin YS (2006) Ceramide in apoptotic signaling and anticancer therapy. Curr Med Chem 13: 1609–1616. pmid:16787207
- 13. Mullen TD, Obeid LM (2012) Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med Chem 12: 340–363. pmid:21707511
- 14. Young MM, Kester M, Wang HG (2013) Sphingolipids: regulators of crosstalk between apoptosis and autophagy. J Lipid Res 54: 5–19. pmid:23152582
- 15. Ogretmen B, Hannun YA (2001) Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat 4: 368–377. pmid:12030784
- 16. Reynolds CP, Maurer BJ, Kolesnick RN (2004) Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206: 169–180. pmid:15013522
- 17. Wu CH, Cao C, Kim JH, Hsu CH, Wanebo HJ, Bowen WD, et al. (2012) Trojan-horse nanotube on-command intracellular drug delivery. Nano Lett 12: 5475–5480. pmid:23030797
- 18. Huo HZ, Zhou ZY, Wang B, Qin J, Liu WY, Gu Y (2014) Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun 443: 406–412. pmid:24309100
- 19. Gong L, Yang B, Xu M, Cheng B, Tang X, Zheng P, et al. (2014) Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer Chemother Pharmacol 73: 69–77. pmid:24190701
- 20. Yao C, Wu S, Li D, Ding H, Wang Z, Yang Y, et al. (2012) Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro. Mol Oncol 6: 392–404. pmid:22583777
- 21. Hornemann T, Penno A, Rutti MF, Ernst D, Kivrak-Pfiffner F, Rohrer L, et al. (2009) The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases. J Biol Chem 284: 26322–26330. pmid:19648650
- 22. Kraveka JM, Li L, Bielawski J, Obeid LM, Ogretmen B (2003) Involvement of endogenous ceramide in the inhibition of telomerase activity and induction of morphologic differentiation in response to all-trans-retinoic acid in human neuroblastoma cells. Arch Biochem Biophys 419: 110–119. pmid:14592454
- 23. Zecevic A, Menard H, Gurel V, Hagan E, DeCaro R, Zhitkovich A (2009) WRN helicase promotes repair of DNA double-strand breaks caused by aberrant mismatch repair of chromium-DNA adducts. Cell Cycle 8: 2769–2778. pmid:19652551
- 24. Edmonds Y, Milstien S, Spiegel S (2011) Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. Pharmacol Ther 132: 352–360. pmid:21906625
- 25. Yao C, Wei JJ, Wang ZY, Ding HM, Li D, Yan SC, et al. (2012) Perifosine Induces Cell Apoptosis in Human Osteosarcoma Cells: New Implication for Osteosarcoma Therapy? Cell Biochem Biophys.
- 26. Di Raimondo D, Tuttolomondo A, Butta C, Miceli S, Licata G, Pinto A (2012) Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr Pharm Des 18: 4385–4413. pmid:22283779
- 27. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, et al. (2010) Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 6: 1603–1624. pmid:21062159
- 28. Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604–616. pmid:15286740
- 29. Mathias S, Pena LA, Kolesnick RN (1998) Signal transduction of stress via ceramide. Biochem J 335 (Pt 3): 465–480. pmid:9794783
- 30. Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9: 459–469. pmid:23774812
- 31. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED Jr. (1972) Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 52: 633–652. pmid:4337477
- 32. Ding W, Yang L, Zhang M, Gu Y (2012) Reactive oxygen species-mediated endoplasmic reticulum stress contributes to aldosterone-induced apoptosis in tubular epithelial cells. Biochem Biophys Res Commun 418: 451–456. pmid:22281495
- 33. Chun TY, Pratt JH (2004) Non-genomic effects of aldosterone: new actions and questions. Trends Endocrinol Metab 15: 353–354. pmid:15380805
- 34. Patel BM, Mehta AA (2012) Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. Eur J Pharmacol 697: 1–12. pmid:23041273
- 35. Lai L, Pen A, Hu Y, Ma J, Chen J, Hao CM, et al. (2007) Aldosterone upregulates vascular endothelial growth factor expression in mouse cortical collecting duct epithelial cells through classic mineralocorticoid receptor. Life Sci 81: 570–576. pmid:17655877
- 36. Yuan Y, Chen Y, Zhang P, Huang S, Zhu C, Ding G, et al. (2012) Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. Free Radic Biol Med 53: 30–43. pmid:22608985
- 37. Luo Y, Rui HL, Chen YP (2006) [The role of MAPK/ERK1/2 signaling pathway in aldosterone stimulated transforming growth factor-beta1 synthesis in renal tubular epithelial cells]. Zhonghua Yi Xue Za Zhi 86: 3133–3137. pmid:17313766
- 38. Terada Y, Ueda S, Hamada K, Shimamura Y, Ogata K, Inoue K, et al. (2012) Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1. Clin Exp Nephrol 16: 81–88. pmid:22042038
- 39. Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, et al. (2012) Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 126: 963–974. pmid:22787113
- 40. Toda N, Nakanishi S, Tanabe S (2013) Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol 168: 519–533. pmid:23190073
- 41. Veldman RJ, Klappe K, Hoekstra D, Kok JW (1998) Metabolism and apoptotic properties of elevated ceramide in HT29rev cells. Biochem J 331 (Pt 2): 563–569. pmid:9531498
- 42. Babia T, Veldman RJ, Hoekstra D, Kok JW (1998) Modulation of carcinoembryonic antigen release by glucosylceramide—implications for HT29 cell differentiation. Eur J Biochem 258: 233–242. pmid:9851714
- 43. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R (1995) Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82: 405–414. pmid:7634330
- 44. Jaffrezou JP, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, et al. (1996) Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. Embo J 15: 2417–2424. pmid:8665849
- 45. Myrick D, Blackinton D, Klostergaard J, Kouttab N, Maizel A, Wanebo H, et al. (1999) Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide. Leuk Res 23: 569–578. pmid:10374850
- 46. Yu T, Li J, Qiu Y, Sun H (2011) 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, JNK activation, and inhibiting PI3K/AKT activation. Mol Cell Biochem 361: 47–54. pmid:21959977
- 47. Dijkhuis AJ, Klappe K, Jacobs S, Kroesen BJ, Kamps W, Sietsma H, et al. (2006) PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. Mol Cancer Ther 5: 593–601. pmid:16546973
- 48. Sietsma H, Veldman RJ, Kolk D, Ausema B, Nijhof W, Kamps W, et al. (2000) 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin Cancer Res 6: 942–948. pmid:10741719